Synonym
Mazipredone; Mazipredona; Mazipredonum
IUPAC/Chemical Name
11beta,17-Dihydroxy-21-(4-methyl-1-piperazinyl)pregna-1,4-diene-3,20-dione
InChi Key
CZBOZZDZNVIXFC-VRRJBYJJSA-N
InChi Code
InChI=1S/C26H38N2O4/c1-24-8-6-18(29)14-17(24)4-5-19-20-7-9-26(32,25(20,2)15-21(30)23(19)24)22(31)16-28-12-10-27(3)11-13-28/h6,8,14,19-21,23,30,32H,4-5,7,9-13,15-16H2,1-3H3/t19-,20-,21-,23+,24-,25-,26-/m0/s1
SMILES Code
C[C@@]12[C@](C(CN3CCN(C)CC3)=O)(O)CC[C@@]1([H])[C@]4([H])CCC5=CC(C=C[C@]5(C)[C@@]4([H])[C@@H](O)C2)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
442.60
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Gazdag M, Babják M, Brlik J, Mahó S, Tuba Z, Görög S. Estimation of impurity profiles of drugs and related materials Part 18. Impurities and degradation products of mazipredone. J Pharm Biomed Anal. 1998 Sep 1;17(6-7):1029-36. PubMed PMID: 9884192.
2: Kiss G, Radványi S, Szigeti G, Lukáts B, Nagy G. New combination for the therapy of canine otitis externa. II. Efficacy in vitro and in vivo. J Small Anim Pract. 1997 Feb;38(2):57-60. PubMed PMID: 9065883.
3: Görög S, Balogh G, Csehi A, Csizér E, Gazdag M, Halmos Z, Hegedüs B, Herényi B, Horváth P, Laukó A. Estimation of impurity profiles in drugs and related materials. Part 11--The role of chromatographic and spectroscopic methods in the estimation of side-reactions in drug syntheses. J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1219-26. Review. PubMed PMID: 8123737.
4: Görög S. The paradigm shifting role of chromatographic methods in pharmaceutical analysis. J Pharm Biomed Anal. 2012 Oct;69:2-8. doi: 10.1016/j.jpba.2012.01.031. Epub 2012 Jan 30. Review. PubMed PMID: 22341481.
5: Görög S, Babják M, Balogh G, Brlik J, Csehi A, Dravecz F, Gasdag M, Horváth P, Laukó A, Varga K. Drug impurity profiling strategies. Talanta. 1997 Sep;44(9):1517-26. PubMed PMID: 18966892.
6: Görög S, Babják M, Balogh G, Brlik J, Dravecz F, Gazdag M, Horváth P, Laukó A, Varga K. Estimation of impurity profiles of drugs and related materials: part 19: theme with variations. Identification of impurities in 3-oxosteroids. J Pharm Biomed Anal. 1998 Dec;18(4-5):511-25. PubMed PMID: 9919951.
7: LUKATS B, TAKACSINAGY G. [COLOR REACTION OF O-DINITROBENZENE AND ITS USE IN MEASURING SOME STEROID COMPOUNDS AND IN THE STUDY OF THE STABILITY OF DEPERSOLONE]. Acta Pharm Hung. 1965 May;35:116-22. Hungarian. PubMed PMID: 14313169.
